Effect of Culicoides sonorensis salivary proteins on clinical disease outcome in experimental Bluetongue virus serotype 8 infection of Dorset sheep

Barbara S. Drolet1*, Lindsey M. Reister1, Christopher J. Lehij1, Piet A. Van Rijn2 & Richard A. Bowen3

1 USDA, Agricultural Research Service, Arthropod-Borne Animal Diseases Research Unit, 1515 College Ave., Manhattan, KS, 66502 USA.
2 Central Veterinary Institute of Wageningen University, Department of Virology, The Netherlands; Centre for Human Metabonomics, North-West University, Department of Biochemistry, Potchefstroom, South Africa.
3 Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO, 80524, USA.

* Corresponding author at: USDA-ARS-ABADRU, 1515 College Ave., Manhattan, KS, 66502 USA. Tel: +1 785 537 5569, e-mail: barbara.drolet@ars.usda.gov.

Keywords
Biting midges, Bluetongue virus, Bluetongue virus serotype 8, Clinical disease, Culicoides sonorensis, Saliva, Sheep, Vector-enhanced transmission.

Summary
The severity of Bluetongue clinical disease in ruminants varies greatly depending on the outbreak serotype/strain, animal species/breed, and immune status of the herd. To predict disease risk from any of the 26 Bluetongue virus (BTV) serotypes identified to date, experimental animal susceptibility studies are often conducted. Although sheep are the most susceptible livestock species in the US, infection of domestic breeds by injection of field isolates rarely produces the level of clinical disease observed in natural Culicoides midge-transmitted outbreaks. Thus, outbreak risk assessments based on experimental animal infections can underestimate the severity posed by a potential outbreak with a given virus serotype or strain. The aim of this study was to determine whether secreted Culicoides salivary proteins injected simultaneously with virus, to more closely mimic midge-delivered virus, would affect clinical disease outcome in a BTV-8 sheep susceptibility study. Eight sheep were intradermally inoculated with BTV-8; 4 received virus mixed with secreted Culicoides salivary proteins (BTV-8 + Cu SP), 4 received virus alone. Clinical signs were monitored daily for type, severity and duration. In sheep receiving the BTV-8 + Cu SP inoculum, clinical signs were more varied, more severe, and duration was three times longer compared to sheep receiving virus alone. These results suggest that Culicoides salivary proteins may play a contributing role in BTV pathology and that use of these proteins in experimental animal infections may allow development of a more robust target-host animal model.

Keywords
Bluetongue, Culicoides sonorensis, Moscerino, Pecora, Saliva, Sierotipo 8 del virus della Bluetongue, Vettore.

Riassunto
La sintomatologia clinica della Bluetongue (BT) varia notevolmente a seconda del sierotipo/ceppo del virus responsabile, della specie/razza e dello stato immunitario dell’animale infettato. Per valutare il rischio di infezione da parte dei 26 sierotipi del virus della Bluetongue (BTV) fino ad oggi identificati si infettano sperimentalmente animali suscettibili. Negli Stati Uniti la pecora risulta la specie più sensibile. Si è potuto constatare che l’infezione sperimentale di razze domestiche difficilmente riproduce i quadri clinici osservati nelle infezioni naturali quando il virus è trasmesso da Culicoides. Le valutazioni sul rischio epidemico basate sui risultati delle infezioni sperimentali possono pertanto indurre a sottovalutare la pericolosità di una potenziale epidemia. In questo studio, per riprodurre più fedelmente il contagio da Culicoides, le proteine salivari di Culicoides sono state iniettate nell’animale.
### Introduction

In the US, 5 serotypes of Bluetongue virus (BTV) are considered endemic or ‘domestic’ (BTV-2, BTV-10, BTV-11, BTV-13, BTV-17). Each serotype results in varying disease levels in target species such as white-tailed deer, cattle, and sheep. However, since 1999, 10 incursive or ‘exotic’ BTV serotypes have been detected, some repeatedly, in wildlife and livestock (Corn et al. 2013, Ostlund 2009, Ostlund 2013, Stallknecht 2009). This suggests BTV serotype introductions are quite routine and consistent in North America. One serotype of concern to livestock producers is BTV-8, which resulted in unprecedented geographic spread and livestock morbidity and mortality in Northern Europe during the 2006-2007 Culicoides vector seasons. In the US, sheep are the most susceptible livestock species, and Polled Dorsets have become the second largest white-faced sheep breed. Clinical disease can include: fever, ulcers on the tongue, mouth and nostrils, ocular and nasal discharge, conjunctivitis, facial edema, excessive salivation, cyanotic (blue) tongue, respiratory distress, coroni, loss of appetite, and depression. Severity and form of clinical disease in a specific species vary greatly depending on the outbreak serotype or specific strain within a serotype and on the immune status of herds during the vector season. A recent example of this variation in pathology was seen in the 2007 BTV-17 outbreak in Wyoming, US, with sheep flocks suffering up to 36% morbidity and 35% mortality. This was in contrast to prior outbreaks of this serotype, which were historically considered relatively mild (Miller et al. 2010).

Experimental animal infections are typically used to understand pathogenesis and predict disease severity of future outbreaks with endemic and incursive BTV serotypes. The value of such studies can be limited, however, because unlike natural infections, routine experimental infection of domestic US sheep breeds by inoculation only rarely produces clinical disease beyond a transient fever and mild clinical signs depending on the infectious dose, inoculation route, and the BTV serotype used. This is contrary to what is usually observed in natural infections where virus is transmitted by the bite of a Culicoides midge and may result in severe clinical disease with 30-50% mortality. It has been hypothesised that the more severe clinical disease levels seen in natural, midge-transmitted outbreaks is due to intradermal route of virus delivery, as well as interactions of the vector's saliva with the virus, with the animal's immune responses, or with both. This ‘vector-enhanced’ transmission has been reported for several arboviruses (Bergman et al. 2000, Cupp and Cupp 1997, Darpel et al. 2011, de Moura et al. 2007, Gillespie et al. 2000, Hajnicka et al. 1998, Hajnicka et al. 2000, Kocakova et al. 1999, Limesand et al. 2003, Ribeiro 1987, Tabachnick 2000, Urioste et al. 1994). The inability to replicate BT clinical disease in North American sheep by experimental inoculation can result in risk assessments underestimating the severity posed by a given virus serotype or strain. The aim of this study was to determine whether artificially mixing BTV inocula with secreted salivary proteins of *Culicoides sonorensis*, the primary BTV vector in the US, would result in a vector-enhanced Bluetongue clinical disease sheep model mimicking more precisely what is observed in natural bite-transmission infections of sheep in the US.

### Materials and methods

#### Culicoides sonorensis salivary proteins

Salivary proteins were collected from *Culicoides sonorensis* (BTV-8 + Cu SP), ad ulteriori 4 pecore è stato somministrato il solo BTV. I sintomi clinici sono stati monitorati giornalmente per tipo, gravità e durata. Negli ovini inoculati con BTV-8 + Cu SP, i sintomi clinici sono risultati più eterogenei, più gravi e di una durata 3 volte superiore a quella delle pecore trattate con il solo virus. I risultati ottenuti suggeriscono che le proteine salivari di *Culicoides* possono influenzare la virulenza del BTV e che l'uso di queste proteine nelle infezioni sperimentali potrebbe consentire lo sviluppo di modelli animali più conformi alle infezioni naturali.

### Culicoides salivary proteins and BTV clinical disease

Drolet et al.
University (Lelystad, the Netherlands). The BTV-8 inoculum was EDTA-blood harvested from Holstein Frisian cow NL441689187 from Bavel (the Netherlands); this was the first detected case of BTV-8 after overwintering (GenBank GQ506451-GQ506460) (Backx et al. 2007). The blood inoculum titer was previously determined to be $6 \times 10^5$ particles/ml by quantitative real time polymerase chain reaction (qRT-PCR) and RNA/virus particle determinations (Akita et al. 1992, Drolet et al. 2013). Each experimental sheep received 1 ml of the blood inoculum in 2 locations for a total of $1.2 \times 10^6$ particles. For the BTV-8 inocula containing Culicoides salivary proteins (BTV-8+Cu SP), 1 ml of the above blood inoculum was combined with 250 ul (100 ug) C. sonorensis salivary proteins, resulting in a total inoculum volume of 1.25 ml per injection location.

**Sheep inoculations**

A total of 8 BTV-seronegative American Poll Dorset yearlings were sedated with xylazine (0.05-0.1 mg/kg) and injected with BTV-8/NET2007/01 bovine blood stock virus intradermally (cluster of 10, 0.1ml injections) in the neck and inner left leg. Four of these sheep were inoculated with BTV-8 (Group A, 1 ml total volume/site), and 4 with BTV-8 + Cu SP (Group B, 1.25 ml total volume/site). Two negative control sheep were sham inoculated with uninfected bovine blood and housed with infected animals to examine direct contact transmission (1 per each experimental group). Body temperatures and clinical signs were scored daily on a scale of 0-3 with 0 being normal and 3 being severe. Two challenged animals (1 per group) were euthanized with pentobarbitol at the anticipated peak of viremia (day 8) and the remaining were held until day 28.

**Results**

Clinical signs of Bluetongue disease in groups A (BTV-8) and B (BTV-8 + Cu SP) were monitored daily. Sheep were characterised as febrile when rectal temperatures were > 39°C. Both groups showed similar degree ranges. However, the temperatures of sheep in Group B peaked 1 day earlier than the temperatures of sheep in Group A (Figure 1). Visible clinical signs were recorded daily using a scale of 0‑3 (0 = normal, 1 = mild, 2 = moderate, 3 = severe) and included ocular discharge, nasal discharge, conjunctivitis, excessive salivation, oral ulcers, facial edema, coronitis, diarrhea, and respiratory distress (Table I). In both groups, excessive salivation directly correlated with the presence of oral ulcers was observed. Animal to animal variation was seen in both groups; yet, Group B (BTV-8 + Cu SP) showed more types and more severe clinical disease.

In Group A (BTV-8), the duration of clinical signs lasted from day 7 to day 9, moderate to severe ocular and nasal discharge being the most common signs observed. At the peak of clinical disease, 3 sheep had ocular and nasal discharge, 1 had mild conjunctivitis, 1 had moderate oral lesions and excessive salivation, 2 had moderate facial edema and 1 had moderate coronitis.

**Figure 1.** Febrile response to Bluetongue virus serotype 8 (BTV-8) inoculation. Rectal temperatures (°C) of sheep inoculated with BTV-8 (blue line) or BTV-8 mixed with Culicoides sonorensis midge salivary proteins (red line). Average normal temperature of negative controls for 28 days was 39°C.
In Group B (BTV-8 + Cu SP), the duration of clinical disease lasted from day 3 to day 11, 3 times longer than Group A. Moderate to severe ocular and nasal discharge were the most common clinical signs observed (Figure 2). At the peak of clinical disease, all 4 sheep had ocular and nasal discharge and conjunctivitis. One sheep had moderate oral ulcers and excessive salivation, 2 had severe facial edema, 3 had moderate to severe coronitis, 2 had moderate to severe diarrhea and 1 had moderate respiratory distress.

Because sheep were housed 5 per room and shared food and water, individual scores for loss of appetite were not possible, but an overall loss of appetite was noted in both groups on days 8 and 9. Depression was also seen in both groups and was characterised by listlessness, lowered heads, and slow or diminished avoidance of human contact. Clinical disease signs were not observed in the 2 sham inoculated negative control sheep which were housed with the inoculated sheep, confirming no direct contact transmission.

**Discussion**

Natural, *Culicoides*-transmitted BTV outbreaks in US sheep herds can result in severe clinical disease with 30-50% mortality. Conversely, routine experimental infection by virus inoculation of virulent field isolates rarely results in clinical disease beyond a transient fever. This phenomenon has been seen repeatedly for BTV by our lab over the past 30 years and reported by others with several serotypes of BTV (Backx et al. 2007, Darpel et al. 2007), and other viruses such as Epizootic haemorrhagic disease (Breard et al. 2013), Schmallenberg (Wernike et al. 2012, Wernike et al. 2013) and Rift Valley fever (Drolet et al. 2012). In order to perform evaluative research on pathogenesis, immune response, and vaccine candidate efficacy, there is a need for consistent, reliable and well-characterised BTV sheep challenge models. Salivary proteins have been linked to the efficient vector-to-animal transmission of a number of arboviruses including West Nile (Schneider et al. 2006), Sindbis (Schneider et al. 2004), Dengue fever (Espada-Murao and Morita 2011), and vesicular stomatitis (Limesand et al. 2000). Interestingly, a recent report involving *C. sonorensis* saliva has suggested that protein components may be involved in the efficient transmission of BTV from an infected host into the midge vector by interacting directly with the VP2 protein of the virus (Darpel et al. 2011). The question remains, however, as to how this would increase bite transmission efficiency from midge to animal since in the same study, viral infection of mammalian cell cultures decreased 2-6 fold. Whether by direct interaction with arboviruses or immunomodulation of the vertebrate host's response to those arboviruses, it is clear that insects play a critical role in arbovirus infection efficiency and resulting clinical disease. Thus, insects should be used for arbovirus transmission and infection

**Table I. Heat map representation of peak clinical Bluetongue disease in sheep inoculated with either Bluetongue virus serotype 8 (BTV-8) or BTV-8 mixed with *Culicoides sonorensis* salivary proteins.**

<table>
<thead>
<tr>
<th>BTV-8</th>
<th>BTV-8 + <em>Culicoides</em> salivary proteins</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sheep 1</td>
<td>Sheep 2</td>
</tr>
<tr>
<td>Ocular discharge</td>
<td><img src="image" alt="Ocular discharge" /></td>
</tr>
<tr>
<td>Nasal discharge</td>
<td><img src="image" alt="Nasal discharge" /></td>
</tr>
<tr>
<td>Conjunctivitis</td>
<td><img src="image" alt="Conjunctivitis" /></td>
</tr>
<tr>
<td>Excessive salivation</td>
<td><img src="image" alt="Excessive salivation" /></td>
</tr>
<tr>
<td>Oral ulcers</td>
<td><img src="image" alt="Oral ulcers" /></td>
</tr>
<tr>
<td>Facial edema</td>
<td><img src="image" alt="Facial edema" /></td>
</tr>
<tr>
<td>Coronitis</td>
<td><img src="image" alt="Coronitis" /></td>
</tr>
<tr>
<td>Diarrhea</td>
<td><img src="image" alt="Diarrhea" /></td>
</tr>
<tr>
<td>Respiratory distress</td>
<td><img src="image" alt="Respiratory distress" /></td>
</tr>
</tbody>
</table>

□ = 0, normal; □ = 1, mild; □ = 2, moderate; □ = 3, severe.
research; however, logistically this is difficult. The lack of colonized insect sources, access to facilities that allow insect/animal work, ensuring proper containment of insects during the experiment, and the inherent variability in virus dose delivery during insect feeding results in the continued use of insect bite versus insect transmission of virus to experimentally infect animals.

Results from this preliminary study show that sheep receiving virus and C. sonorensis salivary proteins exhibited more varied and severe clinical disease, and the duration of disease was 3 times longer compared to sheep receiving virus alone. This suggests that artificially mixing C. sonorensis salivary proteins with BTV in experimental inocula may offer an experimental target-host animal model that better represents natural bite transmission and allow for more accurate examination of factors contributing to susceptibility, pathogenesis, vaccine efficacy, and outbreak disease risk assessments.

**Acknowledgements**

We thank Jim Kempert and Bill Yarnell (ABADRU) for providing colony insects for salivary protein collections. Funding for this research was provided by the USDA, ARS, NP103 Animal Health National Program, Project Number 3020-32000-006 and NP104 Medical, Veterinary, and Urban Entomology National Program, Project Number 3020-32000-007. Mention of trade names or commercial products in this publication is solely for the purpose of providing specific information and does not imply recommendation or endorsement by the USDA.

**References**


